Wednesday, June 24, 2020 7:20:03 PM
1. PSS lawsuit worth $1.2B+
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial data
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (2-3 mos).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. Scilex potential IPO
18. FDA approval of COVI-TRACK
19. Sales begin for COVI-TRACK
20. Several cancer trials with first-in-class DAR-T are coming
21. Abivirtinib phase 2 in Covid begins in August
22. Water soluble CBD partnership
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
- Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM
PickleJar Debuts Nationwide Contest With Brian Kelley for Fans to Win a Three-Day Bahama Cruise • NREG • Jun 3, 2024 8:45 AM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM